<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01968707</url>
  </required_header>
  <id_info>
    <org_study_id>EM-012760</org_study_id>
    <nct_id>NCT01968707</nct_id>
  </id_info>
  <brief_title>In-vivo Efficacy Study of Patient Pre-operative Preps</brief_title>
  <official_title>Assessment of the Antimicrobial Efficacy of 3M CHG/IPA Preoperative Skin Preparation Against Resident Human Skin Flora on the Abdominal and Inguinal Regions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>3M</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the antimicrobial efficacy of the 3M CHG/IPA Prep
      on skin flora of the abdomen and inguinal regions of human subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A 2-log per cm2 bacterial reduction on the abdomen and a 3-log per cm2 bacterial reduction on the inguinal region.</measure>
    <time_frame>10 minutes post-product application</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin flora does not return to baseline on the abdomen and inguinal region.</measure>
    <time_frame>6 hours post-product application</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by Skin Irritation score and Adverse Events</measure>
    <time_frame>10 minute to 6 hour post-product application</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">510</enrollment>
  <condition>Bacterial Reduction on Skin Flora Post-product Application</condition>
  <arm_group>
    <arm_group_label>ChloraPrep CHG/IPA Hi-Lite Orange Tint</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chlorhexidine gluconate 2% / Isopropyl alcohol 70%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% normal saline with applicator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3M CHG/IPA Prep Tint 10.5-mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chlorhexidine gluconate 2% / Isopropyl alcohol 70% 10.5 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3M CHG/IPA Prep Tint 26-mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chlorhexidine gluconate 2% / Isopropyl alcohol 70% 26 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ChloraPrep CHG/IPA Hi-Lite Orange Tint</intervention_name>
    <description>Apply topically.</description>
    <arm_group_label>ChloraPrep CHG/IPA Hi-Lite Orange Tint</arm_group_label>
    <other_name>ChloraPrep</other_name>
    <other_name>Chlorhexidine gluconate 2% / Isopropyl alcohol 70%</other_name>
    <other_name>Chlorhexidine gluconate 2% w/v / Isopropyl alcohol 70% v/v</other_name>
    <other_name>2% CHG / 70% IPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Apply topically.</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>0.9% Sodium Chloride</other_name>
    <other_name>Sterile Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3M CHG/IPA Prep Tint 10.5-mL</intervention_name>
    <description>Apply topically.</description>
    <arm_group_label>3M CHG/IPA Prep Tint 10.5-mL</arm_group_label>
    <other_name>Chlorhexidine gluconate 2% / Isopropyl alcohol 70%</other_name>
    <other_name>Chlorhexidine gluconate 2% w/v / Isopropyl alcohol 70% v/v</other_name>
    <other_name>2% CHG / 70% IPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3M CHG/IPA Prep Tint 26-mL</intervention_name>
    <description>Apply topically</description>
    <arm_group_label>3M CHG/IPA Prep Tint 26-mL</arm_group_label>
    <other_name>Chlorhexidine gluconate 2% / Isopropyl alcohol 70%</other_name>
    <other_name>Chlorhexidine gluconate 2% w/v / Isopropyl alcohol 70% v/v</other_name>
    <other_name>2% CHG / 70% IPA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of any race

          -  Subjects in good general health

          -  Minimum skin flora baseline requirements on abdomen and groin

        Exclusion Criteria:

          -  Any tattoos, scars, breaks in the skin, or any form of dermatitis, or other skin
             disorders (including acne) on the applicable test areas

          -  Topical antimicrobial exposure within 14 days prior to screening and treatment days

          -  Use of systemic or topical antibiotics, steroid medications, or any other products
             known to affect the normal microbial flora of the skin within 14 days prior to
             screening and treatment days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad H Bashir, MD, CCRP</last_name>
    <role>Principal Investigator</role>
    <affiliation>MICROBIOTEST</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Microbiotest</name>
      <address>
        <city>Sterling</city>
        <state>Virginia</state>
        <zip>20164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2013</study_first_submitted>
  <study_first_submitted_qc>October 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2013</study_first_posted>
  <disposition_first_submitted>March 25, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 25, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 15, 2015</disposition_first_posted>
  <last_update_submitted>May 13, 2015</last_update_submitted>
  <last_update_submitted_qc>May 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>surgical prep</keyword>
  <keyword>CHG</keyword>
  <keyword>IPA</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

